Stock Events

Stock Events

Alterity Therapeutics 

0
35
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 28Expected
Q4 2025
Q2 2026
-0.03
-0.02
-0.01
-0
Expected EPS
-0.007923624855431998
Actual EPS
-0.003183423325368

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-13.82MNet Income

Analyst Ratings

$9.11Average Price Target
The highest estimate is ⁦12.14⁩.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBNN.STU. It's not an investment recommendation.
Apple
5
AAPL
Amazon
4
AMZN
Tesla
4
TSLA
Microsoft
3
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, directly competing with Alterity's focus on Parkinson's and Alzheimer's.
Palatin Technologies
PTN
Mkt Cap8.9M
Palatin Technologies works on novel therapeutics for diseases with a significant unmet medical need, including neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.55B
Acadia Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurodegenerative disease space.
AnaptysBio
ANAB
Mkt Cap1.44B
AnaptysBio is involved in developing therapeutic antibodies, potentially competing in the neurodegenerative disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap110.31M
Anavex Life Sciences Corp. focuses on developing drugs for Alzheimer's disease and other central nervous system diseases.
Axsome Therapeutics
AXSM
Mkt Cap7.57B
Axsome Therapeutics develops therapies for central nervous system disorders, including Alzheimer's, directly competing with Alterity.
Ionis Pharmaceuticals
IONS
Mkt Cap7.23B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, including for neurological disorders, competing in the same space as Alterity.
Prothena
PRTA
Mkt Cap434.82M
Prothena Corporation is focused on the discovery and development of novel antibodies for neurodegenerative diseases.
Voyager Therapeutics
VYGR
Mkt Cap105.98M
Voyager Therapeutics focuses on severe neurological diseases through gene therapy, competing in the broader neurodegenerative treatment market.

About

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
Show More
CEO
David A. Stamler
Employees
11
Country
Australia
ISIN
US02155X1063
WKN
000A3D4GD

Listings

AU
AU
ATH.AU
MU
DE
PBNN.MU
STU
DE
PBN.STU
STU
DE
PBN0.STU

0 Comments

Share your thoughts

FAQs

What is Alterity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Alterity Therapeutics stocks are traded under the ticker PBNN.STU.
When is the next Alterity Therapeutics earnings date?▼
Alterity Therapeutics is going to release the next earnings report on March 4, 2027.
What were Alterity Therapeutics earnings last quarter?▼
PBNN.STU earnings for the last quarter are -0 EUR per share, whereas the estimation was -0.01 EUR resulting in a +59.82% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Alterity Therapeutics revenue for the last year?▼
Alterity Therapeutics revenue for the last year amounts to 0 EUR.
What is Alterity Therapeutics net income for the last year?▼
PBNN.STU net income for the last year is -13.82M EUR.
How many employees does Alterity Therapeutics have?▼
As of November 7, 2026, the company has 11 employees.
In which sector is Alterity Therapeutics located?▼
Alterity Therapeutics operates in the Health & Wellness sector.
When did Alterity Therapeutics complete a stock split?▼
The last stock split for Alterity Therapeutics was on January 9, 2023 with a ratio of 1:10.
Where is Alterity Therapeutics headquartered?▼
Alterity Therapeutics is headquartered in Melbourne, Australia.